Study finds middlemen excluded nearly 850 medicines from formularies this year
By Katie Koziara | September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...
Read More
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
By Gabby Migliara | August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...
Read More
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
By Gabby Migliara | August 12, 2020
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...
Read More
Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines
By Gabby Migliara | August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...
Read More
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
By Katie Koziara | August 5, 2020
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights...
Read More
New data show commercially insured patients face increasingly high cost sharing for brand medicines
By Gabby Migliara | July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions
By Gabby Migliara | July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
By Gabby Migliara | July 14, 2020
A new study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite...
Read More
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
By Gabby Migliara | June 1, 2020
The two largest pharmacy benefit managers (PBMs), CVS Caremark and Express Scripts, have once again increased the number of medicines on their standard formulary exclusion lists. Medicines...
Read More
New rule makes it harder for patients to lower their out-of-pocket costs
By Holly Campbell | May 20, 2020
In the midst of increased financial insecurity for Americans due to the COVID-19 pandemic, it is shocking the Administration finalized a policy change in the 2021 Notice of Benefit and Payment...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
